Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 1/20 | 0.45 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.44 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.44 |
| ▸ | CSNK1D | P48730 | 6/20 | 0.42 |
| ▸ | CSNK1A1 | P48729 | 5/20 | 0.42 |
| ▸ | GSK3B | P49841 | 4/20 | 0.42 |
| ▸ | CSNK1G2 | P78368 | 4/20 | 0.42 |
| ▸ | METAP2 | P50579 | 1/20 | 0.41 |
| ▸ | METAP1 | P53582 | 1/20 | 0.41 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.39 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.38 |
| ▸ | TTK | P33981 | 1/20 | 0.37 |
| ▸ | ITK | Q08881 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | CHUK | O15111 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL203218 | 0.85 | IMPDH2 (0.43) | PIN1PKN1PKN2CSNK1DCSNK1A1 | |
| Water SCHEMBL11184905 | 0.76 | KMT2A (0.42) | PIN1METAP2METAP1ALDH1A1 | |
| SCHEMBL29424103 | 0.74 | KMT2A (0.43) | PIN1METAP2METAP1ALDH1A1 | |
| SCHEMBL29424102 | 0.74 | KMT2A (0.43) | PIN1METAP2METAP1ALDH1A1 | |
| SCHEMBL2611832 | 0.74 | KMT2A (0.43) | PIN1METAP2METAP1ALDH1A1 | |
| Benzotriazole SCHEMBL14975700 | 0.73 | PIK3CA (0.44) | ALDH1A1 | |
| SCHEMBL16968392 | 0.72 | ALDH1A1 (0.32) | CSNK1DCSNK1G2ALDH1A1 | |
| SCHEMBL4104023 | 0.69 | METAP2 (0.44) | METAP2NOS1ALDH1A1CYP2A6 | |
| SCHEMBL735804 | 0.69 | PRKCI (0.48) | ALDH1A1 | |
| SCHEMBL12871076 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665718-A1 | SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF | Apogee Pharmaceuticals, Inc. (CA) | 2025-12-24 | — | — | EP | disclosed |
| WO-2024168426-A1 | SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF | APOGEE PHARMACEUTICALS, INC. (CA) | 2024-08-22 | — | — | WO | disclosed |
| US-10756394-B2 | Nonaqueous electrolyte and nonaqueous secondary battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2020-08-25 | — | — | US | disclosed |
| CN-106420754-B | The purposes of benzo five-membered Azacyclyl bridged piperazine derivatives | 沈阳海王生物技术有限公司 | 2019-11-05 | — | — | CN | disclosed |
| CN-108721289-A | The purposes of benzo five-membered Azacyclyl piperidine derivative | 沈阳海王生物技术有限公司 | 2018-11-02 | — | — | CN | disclosed |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2018-03-01 | — | — | US | disclosed |
| US-9802929-B2 | Benzo five-membered nitrogen heterocyclic piperidine or piperazine derivatives and preparation methods and pharmaceutical compositions thereof | SHENYANG HAIWANG BIOTECHNOLOGY CO., LTD. (CN) | 2017-10-31 | — | — | US | disclosed |
| US-9415047-B2 | Use of benzo five-membered nitrogen heterocyclic piperazine or piperidine derivatives | Liaoning Emmy Biological Pharmaceutical Co., Ltd. (CN) | 2016-08-16 | — | — | US | disclosed |
| US-20160009703-A1 | BENZO FIVE-MEMBERED NITROGEN HETEROCYCLIC PIPERIDINE OR PIPERAZINE DERIVATIVES AND PREPARATION METHODS AND PHARMACEUTICAL COMPOSITIONS THEREOF | LIAONING EMMY BIOLOGICAL PHARMACEUTICAL CO., LTD (CN) | 2016-01-14 | — | — | US | disclosed |
| US-20150297586-A1 | USE OF BENZO FIVE-MEMBERED NITROGEN HETEROCYCLIC PIPERAZINE OR PIPERIDINE DERIVATIVES | Liaoning Emmy Biological Pharmaceutical Co., Ltd. (CN) | 2015-10-22 | — | — | US | disclosed |
| EP-0897556-A1 | SILVER-HALIDE RECORDING MATERIAL WITH IMPROVED STORAGE STABILITY TO PRODUCE NEGATIVES WITH ULTRAHARD-GRADATION CONTRAST | Agfa-Gevaert AG (DE) | 1999-02-24 | — | — | EP | disclosed |
| EP-0880059-A1 | Silver halide photographic material and process for forming silver images | DU PONT DE NEMOURS (DEUTSCHLAND) GMBH (DE) | 1998-11-25 | — | — | EP | disclosed |
| US-5783357-A | BLACK AND WHITE PHOTOGRAPHY | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1998-07-21 | — | — | US | disclosed |
| EP-0740194-B1 | Silver halide containing material for making negative images having ultrahigh contrast | DU PONT DEUTSCHLAND (DE) | 1998-04-01 | — | — | EP | disclosed |
| WO-1997042545-A1 | SILVER-HALIDE RECORDING MATERIAL TO PRODUCE NEGATIVES WITH REDUCED FOG AND ULTRAHARD-GRADATION | AGFA-GEVAERT AG (DE) | 1997-11-13 | — | — | WO | disclosed |
| WO-1997042546-A1 | SILVER-HALIDE RECORDING MATERIAL WITH IMPROVED STORAGE STABILITY TO PRODUCE NEGATIVES WITH ULTRAHARD-GRADATION CONTRAST | AGFA-GEVAERT AG (DE) | 1997-11-13 | — | — | WO | disclosed |
| EP-0618491-B1 | Method for generation of negative images having ultrahigh contrast | DU PONT DEUTSCHLAND (DE) | 1997-08-27 | — | — | EP | disclosed |
| EP-0740194-A1 | Silver halide containing material for making negative images having ultrahigh contrast | DU PONT DE NEMOURS (DEUTSCHLAND) GMBH (DE) | 1996-10-30 | — | — | EP | disclosed |
| EP-0733939-A1 | Siver halide recording material for generation of negative images with ultrahigh contrast | DU PONT DE NEMOURS (DEUTSCHLAND) GMBH (DE) | 1996-09-25 | — | — | EP | disclosed |
| EP-0618491-A1 | Method for generation of negative images having ultrahigh contrast | DU PONT DE NEMOURS (DEUTSCHLAND) GMBH (DE) | 1994-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10756394-B2 | Nonaqueous electrolyte and nonaqueous secondary battery | BPTF, BRD4, KCNN2 | PIN1 1914/4885PKN1 1658/4885PKN2 515/4885 |
| US-20150297586-A1 | USE OF BENZO FIVE-MEMBERED NITROGEN HETEROCYCLIC PIPERAZINE OR PIPERIDINE DERIVATIVES | P2RX5, TBXA2R, CYP3A5 | PIN1 2991/4885PKN1 1458/4885PKN2 981/4885 |
| US-20160009703-A1 | BENZO FIVE-MEMBERED NITROGEN HETEROCYCLIC PIPERIDINE OR PIPERAZINE DERIVATIVES AND PREPARATION METHODS AND PHARMACEUTICAL COMPOSITIONS THEREOF | CYP3A5, IL5, ABCC5 | PIN1 2541/4885PKN1 1347/4885PKN2 602/4885 |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | BPTF, BRD4, KCNN2 | PIN1 1914/4885PKN1 1658/4885PKN2 515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.